[HTML][HTML] A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Background Recent evidence suggested a potential correlation between overweight and the
efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. Patients and methods We …
efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. Patients and methods We …
Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: a real‐world …
Background Patients with a history of autoimmune diseases (AIDs) have not usually been
included in clinical trials with immune checkpoint inhibitors. Materials and Methods …
included in clinical trials with immune checkpoint inhibitors. Materials and Methods …
Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients
Background Immune-related adverse events (irAEs) developed during immunotherapy with
anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with …
anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with …
[HTML][HTML] Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1) …
…, MG Vitale, F Rastelli, M Tudini, RR Silva… - European Journal of …, 2020 - Elsevier
Background Several studies have found an association between higher body mass index (BMI)
and improved clinical outcomes in cancer patients receiving programmed cell death …
and improved clinical outcomes in cancer patients receiving programmed cell death …
[PDF][PDF] Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy
…, R Ficarelli, ET Menichetti, D Mari, E Testa, R Silva… - J Clin …, 2006 - researchgate.net
… Annamaria Ruzzo, Francesco Graziano, Kazuyuki Kawakami, Go Watanabe, Daniele Santini,
Vincenzo Catalano, Renato Bisonni, Emanuele Canestrari, Rita Ficarelli, Ettore Tito Menichetti …
Vincenzo Catalano, Renato Bisonni, Emanuele Canestrari, Rita Ficarelli, Ettore Tito Menichetti …
[HTML][HTML] Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study
Background Data on spectrum and grade of immune-related adverse events (irAEs) in long-term
responders to immune checkpoint inhibitors (ICIs) are lacking. Methods We performed …
responders to immune checkpoint inhibitors (ICIs) are lacking. Methods We performed …
Insulin‐like growth factor 1 expression correlates with clinical outcome in K‐RAS wild type colorectal cancer patients treated with cetuximab and irinotecan
…, E Galizia, L Giustini, RR Silva… - … journal of cancer, 2010 - Wiley Online Library
Seventy to 40% of K‐RAS wild type colorectal tumors does not seem to benefit from treatment
with antiepidermal growth factor receptor (anti‐EGFR) monoclonal antibodies. Recent data …
with antiepidermal growth factor receptor (anti‐EGFR) monoclonal antibodies. Recent data …
The Role of HER‐3 Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab
…, A Zaniboni, E Galizia, L Giustini, RR Silva… - The …, 2011 - academic.oup.com
… Rosa Rita Silva , Rosa Rita Silva … ; Alberto Zaniboni: None; Eva Galizia: None; Lucio Giustini:
None; Rosa Rita Silva: None; Renato Bisonni: None; Rossana Berardi: None; Tommasina …
None; Rosa Rita Silva: None; Renato Bisonni: None; Rossana Berardi: None; Tommasina …
Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer
…, A Ruzzo, I Bearzi, B Humar, H More, R Silva… - Clinical Cancer …, 2004 - AACR
Purpose: Recent investigations have demonstrated that hypermethylation is a frequent
mechanism for silencing tumor suppressor genes. This is a potentially reversible epigenetic …
mechanism for silencing tumor suppressor genes. This is a potentially reversible epigenetic …
Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer
…, R Bisonni, P Giordani, L Giustini, P Lippe, R Silva… - 2007 - degruyter.com
Background: Gastric cancer is the second highest cause of cancer mortality in the world,
despite declining rates of incidence in many industrialized countries. We carried out a case-…
despite declining rates of incidence in many industrialized countries. We carried out a case-…